EU Medical Devices Regulation – Unique Device Identifier (UDI)
In 2017, two Regulations on medical devices (MDR) and in in vitro diagnostic medical devices (IVDR) entered into force in the European Union (EU), establishing a modernized and more robust EU legislative framework and safeguarding a better public health protection and patient safety. According to the these Regulations, the Unique Device Identifier (UDI) will be mandatory for all medical devices and in vitro medical devices.


According to the new EU Medical Devices Regulation (MDR – Regulation (EU) 2017/745) and the In Vitro Diagnostic Medical Devices Regulation  (IVDR – Regulation (EU) 2017/746), the “Unique Device Identifier” (UDI) means a “series of numeric or alphanumeric characters that is created through internationally accepted device identification and coding standards and that allows unambiguous identification of specific devices on the market”.

The main goal of the UDI is to allow the identification and improve the traceability of devices. The UDI will also allow a better monitoring by the competent authorities as well as it represents a fighting mechanism against counterfeit medical devices.

The UDI will be mandatory for all medical devices and in vitro medical devices, except for the custom-made and performance study/investigational devices.

The UDI system is described in the Part C of Annex VI of both Regulations and consists of several parts:Production of an UDI:

  • UDI device identifier (‘UDI-DI’), which is specific to a manufacturer and a device;
  • UDI production identifier (‘UDI-PI’), which identifies the unit device production and the package devices (if applicable).
  • Placing the UDI on the label of the device or its packaging (specific requirements);
  • Storage of the UDI by economic operators, health institutions and health care professionals;
  • Establishment of an electronic system for Unique Device Identification (‘UDI database’).

The basic UDI-DI will be the access key for device-related information and therefore is referenced in relevant documentation (e.g., certificates, declaration of conformity, technical documentation). The basic UDI-DI has the objective of identifying (in a unique manner) and connect devices with the same intended purpose.

The label and all higher levels of packaging (not shipping containers) of medical devices must include the UDI information, including the UDI-DI and UDI-PI. In case of reusable devices, the UDI carrier shall be placed on the device itself (direct marking). The UDI-DI of the device should appear on the EU declaration of conformity.

An UDI shall be attributed to a medical device created before placing such device on the market. The manufacturer should ensure that all information required is correctly submitted to the UDI database (European Database on Medical Devices – EUDAMED). Moreover, the manufacture needs to keep up-to-date a list of all UDIs that is has assigned.

The UDI database, integrated with EUDAMED, should be set up and managed by the European Commission, in order to validate, collate, process and make available the information to the public (free of charge, with maximum accessibility).


The UDI assignment will be mandatory from 26th May 2021 for medical devices and from 26th May 2022 for in vitro diagnostic medical devices. When it comes to the submission of UDI data at EUDAMED database, it will be obligatory for medical devices from 26th November 2022 and from 26th November 2023 for in vitro diagnostic medical devices. Manufacturers may voluntarily comply with registration of their medical devices and in vitro medical devices from 26th May 2021 and 26th May 2022, respectively.

When it comes to the obligation of placing the UDI carrier, the timeline will be in accordance with the type of medical device (risk-based). UDI-carriers must be placed on the labels of class III devices by 26 May 2021 as long as for class I devices the timeline is 26 May 2025.

In sum, the manufacturer has the responsibility of assigning and register the UDI (and basic UDI-DI) and placing that information on the label and/or packaging. If a distributor, importer or other natural or legal person assumes the obligations incumbent on manufacturers, it also assumes all relevant responsibilities related to UDI (including labelling).

The UDI system can be complex and medical devices manufacturers must ensure compliance with the MDR and IVDR. Our team is here to assist your company throughout the entire process, turning it simpler and easier to make your medical device available on the EU market.


  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Available at:
  2. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices. Available at:
  3. MDCG 2019-4 . Timelines for registration of device data elements in EUDAMED. Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »